Valneva SE (VALN) FCF Margin (2021 - 2026)
Valneva SE (VALN) posted FCF Margin of 0.21% for Q1 2026, up 99.76% sequentially from 89.17% in Q4 2025, and up 1266.0% YoY from 0.02% in Q1 2025.
Powered by 
Analysis
Valneva SE (VALN) FCF Margin (2021 - 2026) Analysis & Trends
Valneva SE has reported FCF Margin for 6 years, with the latest figure at 0.21% in Q1 2026.
- Quarterly FCF Margin rose 1266.0% year-over-year to 0.21% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 36.87% (down 145.0% YoY) and the FY2025 annual result came in at 36.3%, up 1336.0% from the prior year.
- FCF Margin climbed to 0.21% in Q1 2026 per VALN's latest filing, from 89.17% in the prior quarter.
- Over five years, FCF Margin peaked at 151026.86% in Q3 2023 and troughed at 143171.25% in Q2 2023.
- A 5-year average of 404.29% and a median of 69.97% in 2025 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2023 and 2024: FCF Margin surged 15107951 bps in 2023, then sank 15103676 bps in 2024.
- Over 5 years, FCF Margin stood at 97.51% in 2022, then slumped by 119 bps to 213.39% in 2023, then surged by 85 bps to 31.31% in 2024, then slumped by 185 bps to 89.17% in 2025, then soared by 100 bps to 0.21% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 0.21%, 89.17%, and 69.97% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -388.28% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 25.68% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 22.62% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 70.82% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -22.35% |
| 10 | Valneva SE | 578.54 Mn | 437.28 Mn | 1.86 Mn | -37.44% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -37.44% |
| Mar 31, 2026 | -0.21% |
| Dec 31, 2025 | -48.84% |
| Sep 30, 2025 | -51.96% |
| Jun 30, 2025 | -2.83% |
| Mar 31, 2025 | -12.87% |
| Dec 31, 2024 | 25.26% |
| Sep 30, 2024 | -9.01% |
| Jun 30, 2024 | -97.86% |
| Mar 31, 2024 | -72.68% |
| Dec 31, 2023 | -142.51% |
| Sep 30, 2023 | 151,026.86% |
| Jun 30, 2023 | -143,171.25% |
| Mar 31, 2023 | -59.83% |
| Dec 31, 2022 | -44.87% |
| Sep 30, 2022 | -52.66% |
| Jun 30, 2022 | -92.90% |
| Mar 31, 2022 | -78.49% |
| Dec 31, 2021 | 22.90% |
| Sep 30, 2021 | -79.14% |